Evaluation of Oral EGCG Treatment for L-SIL Associated With HPV Infection
Evaluation of Oral Epigallocatechin Gallate Treatment for Low-grade Cervical Lesions (L-SIL) Associated With Human Papilloma Virus (HPV) Infection
University of Palermo
50 participants
Mar 1, 2024
OBSERVATIONAL
Conditions
Summary
The study aims to evaluate the effectiveness of the synergy of oral Epigallocatechin Gallate as a treatment for Low-grade Cervical Lesions (L-SIL) associated with Human Papilloma Virus (HPV) infection.
Eligibility
Plain Language Summary
Simplified for easier understanding
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Oral treatment with Epigallocatechin Gallate 200 mg per day
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06314113